Meeting report of the “Regulatory Exchange Matters” session at the 5th International TREAT-NMD Conference:

- Good communication among regulators, patients and academics is very important.
- Mutual education of regulators, patients and academics is crucial for rare diseases.
- Patients should be involved in trial design and drug development by academics and industry.
- European Medicines Agency actively involves patients, carers and consumers in regulatory processes.